We have a long history of integrating cutting-edge science and innovative technology to develop products and devices that meet the needs of patients living with difficult-to-treat diseases.

Looking to the future, we’re fueling our R&D engine to generate new treatment options for patients with high unmet medical needs. We have multiple investigational therapies in early to late-stage development, and we’re aiming to transform research into first-in-class and best-in-class medicine by doubling our R&D productivity in oncology, neurology and immunology.

External innovation also remains a key pillar of our strategy, as we are aiming to source more than 50 percent of our future launch assets externally and be more stringent in managing our portfolio.

We are committed to developing new medicines for patients impacted by difficult-to-treat diseases as safely and quickly as possible.

We believe the best way to fulfill this commitment is through clinical studies that evaluate whether the medicine works and is safe, which can lead to the medicine being approved and made available to the broadest number of patients possible.

From first-in-man administration to commercialization, we are pursuing clinical studies involving thousands of patients around the world. Our teams provide global support to achieve regulatory approvals, as well as post-approval and life-cycle management initiatives. Our Clinical Development operations range from early-stage to full clinical development management of the organization's clinical trials. In addition, our Medical Organization, which is focused on advancing scientific and medical knowledge, manages Phase IV studies and registries.

Because clinical studies depend on patient-volunteers, we encourage patients to consider participating in clinical studies. To search for actively recruiting studies or to learn about new experimental medicines being tested visit www.clinicaltrials.gov.

Our Commitment to Improving Diversity & Inclusion in Clinical Trials
As we aspire to make a difference in the lives of patients, we are committed to conducting clinical trials that represent diverse patient populations by focusing on four key pillars. Click here to learn more about our commitment and strategy.

While EMD Serono recognizes the value of a diverse pool of participants in clinical trials, we do not make any employment or contracting decisions based on race, ethnicity, gender, or any other legally protected characteristic or status. Nothing in EMD Serono’s communications regarding clinical trials should be understood otherwise.

Post-Study Access to Experimental Medicine
We recognize that access to experimental medicine after a clinical study ends is often necessary for the continued health and well-being of patients participating in the studies. We also recognize that continued access may be a legal, regulatory and/or ethical obligation under some circumstances. Click here to read our Position Statement on Post-Study Access to Experimental Medicine. 

Clinical trial participants have a critical role in helping scientists find future treatment options. Click here to access the EMD Serono clinical trial website for patients and caregivers to obtain information about our clinical trials and the overall clinical research process, developed in line with our commitment to clinical trial transparency.

External Resources
If you are looking for more information or listings of clinical trials, you can follow these links:

• Clinicaltrials.gov
• World Health Organization Clinical Trials Registry Platform

We also believe that Investigator Sponsored Studies play a valuable role in our development of new medicines. We welcome qualified investigators to submit their study ideas to us for consideration.

For submissions in the therapeutic area of Neurology & Immunology, please visit www.emdserono.com/us-en/neurology-immunology-iss.html.

For all other therapeutics areas, please visit startone.vibrantm.com.